SAN DIEGO — Travere Therapeutics, a biotech focused on treating rare diseases, on Monday announced that a Phase 3 trial of an experimental treatment for focal segmental glomerulosclerosis, a rare and deadly kidney disease, failed to improve kidney function.
In the 371-person study, half of patients were randomly assigned to receive the drug, known as sparsentan, while the other half received irbesartan, a blood pressure treatment used as a control. Both groups were monitored for two years, and while the study’s main measurement — average kidney function — was higher among patients on sparsentan compared to the placebo group, the finding was not statistically significant.
Other secondary measures, such as urine protein levels, were lower among those on the drug, pointing in the right direction, and the company told investors and analysts in a conference call on Monday that the therapy was generally safe.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect